Kestra Medical (KMTS) Q4 2026: Revenue Surges 66% but Losses Widen
As seen on the 24/7 Wall St. homepage on July 14, 2026.
Kestra crushed revenue expectations with a 66% year-over-year surge in wearable defibrillator demand, but losses deepened as the company aggressively scaled its commercial team. The miss on earnings per share signals the bet is all in on FY27 guidance of 44% revenue growth.
Continue ReadingShow less
Kestra Medical Technologies posted Q4 2026 revenue of $28.6 million, beating analyst estimates of roughly $26.5 million by about 8%. That top-line strength was driven by a 66% year-over-year surge in wearable defibrillator demand, a striking acceleration that signals the company is gaining real commercial traction in a competitive cardiac device market.
The bottom line told a different story. Kestra reported a loss of $0.67 per share against an expected loss of $0.58, missing by about 16% as the company poured money into expanding its commercial team. Looking back at recent quarters, the EPS trajectory has been uneven — losses of $1.18 and $1.06 in Q3 and Q4 2025 gave way to narrower misses of $0.36 and $0.45 in the first two quarters of 2026, only for the gap to widen again here. The pattern reflects a company that is deliberately prioritizing growth investment over near-term profitability.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
The key number to watch now is management's FY27 guidance of 44% revenue growth. That forward target is what the current spending binge is designed to deliver, and whether Kestra can sustain the top-line momentum from Q4 while controlling losses will determine how investors treat the stock from here.
Mentioned: KMTS